Eleven of 20 approved drugs target AGTR1, and 10 out of the 11 drugs were Angiotensin II Receptor Blockers (ARBs), one of the most commonly used first-line treatments for hypertension, indicating its potential value in the treatment of IS. This evidence concerns the gene AGTR1 and hypertensive disorder.